Arbutus Biopharma Corporation ABUS Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $160.72M+580% | -$33.5M+20.8% | -$42.28M+22.1% | -$54.25M+29.1% | -$76.57M-9.5% | ||
| $44K-87.9% | $363K-47.0% | $685K-32.2% | $1.01M-25.5% | $1.36M-1.8% | ||
| $4.75M-31.7% | $6.95M-5.1% | $7.32M-10.9% | $8.22M-22.0% | $10.54M+17.2% | ||
| -$34.36M+13.3% | -$39.64M+12.4% | -$45.27M+24.8% | -$60.19M-2.1% | -$58.95M+9.1% | ||
| —— | —— | —— | —— | —— | ||
| $14.56M+154% | $5.72M+4.0% | $5.5M-14.5% | $6.43M-78.8% | $30.35M-41.6% | ||
| -$13.37M+27.0% | -$18.32M-94.1% | -$9.44M— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Arbutus Biopharma Corporation generate?
- Arbutus Biopharma Corporation (ABUS) generated -$34.4M in operating cash flow over the trailing twelve months.
- Where does Arbutus Biopharma Corporation's cash flow data come from?
- Every line is extracted from Arbutus Biopharma Corporation's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
